ERBB2 and breast carcinoma: We discovered that miR-19a-3p is expressed at high levels in breast cancer tissue, particularly in HER2 + and triple-negative breast cancer (TNBC) subtypes, compared to the estrogen receptor-positive (ER +) subtype.